In addition, 100 mg/kg/day ADH-1 in vivo enhances chemotherapeutic efficacy in CDH2-expressing melanoma xenografts but not in CDH2−melanoma xenografts, demonstrating the specificity of ADH-1 to inhibit CDH2.77 The gene discussed is ADH1A; the disease is melanoma.